Key result
Pulmonary vein isolation reduced AF recurrence and burden across 3 sham-controlled trials, though quality-of-life gains were not consistently superior to sham.
Why the study?
This review summarizes the findings and key lessons from sham-controlled trials of pulmonary vein isolation in atrial fibrillation.
Does pulmonary vein isolation reduce AF recurrence and burden and improve quality of life compared to sham ablation in patients with atrial fibrillation?
Does pulmonary vein isolation reduce AF recurrence and burden and improve quality of life compared to sham ablation in patients with atrial fibrillation?
Sham-controlled trials of PVI for atrial fibrillation confirm true reductions in AF recurrence and burden, but show that quality of life improvements are partially driven by nonspecific placebo and Hawthorne effects.
Answers are grounded in this paper and cite their sources.
Nonspecific effects may drive inconsistent quality-of-life gains after pulmonary vein isolation; leaves open net symptomatic benefit beyond arrhythmia reduction.
Purpose of Review This review summarizes the findings and key lessons from sham-controlled trials of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Recent Findings SHAM-PVI, PFA-SHAM, and PVI-SHAM-AF demonstrated lower AF recurrence and burden after PVI compared with sham. Quality of life improved after PVI in all trials, but PVI-SHAM-AF did not show superiority over sham because of similar improvements with sham, reflecting the contribution of nonspecific treatment effects such as expectancy, clinical attention and the Hawthorne effect. The trials demonstrate that invasive sham-controlled studies are feasible, safe, and can achieve blinding. Summary Reductions in AF recurrence and burden with PVI do not consistently translate into greater improvements in quality of life than sham. The contribution of nonspecific treatment effects may have been underestimated in previous trials. Further studies should characterize the relationship between AF burden and symptoms and identify patients most likely to derive symptomatic benefit from PVI.
No takes yet. Share an insight, caveat, or question.
Beimel et al. (2026) conducted a review in Atrial fibrillation. Pulmonary vein isolation (PVI) vs. Sham procedure was evaluated on AF recurrence, AF burden, and quality of life. Pulmonary vein isolation reduced AF recurrence and burden across 3 sham-controlled trials, though quality-of-life gains were not consistently superior to sham.
Synapse has enriched 10 related papers. Consider them for comparative context: